Compare ES & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ES | IQV |
|---|---|---|
| Founded | 1927 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Electric Utilities: Central | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 28.6B |
| IPO Year | 1994 | 2013 |
| Metric | ES | IQV |
|---|---|---|
| Price | $68.47 | $160.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $71.00 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | ★ 100.88 | 4.67 |
| EPS | 4.56 | ★ 7.84 |
| Revenue | ★ $13,547,244,000.00 | $9,739,000,000.00 |
| Revenue This Year | N/A | $6.77 |
| Revenue Next Year | $3.77 | $5.89 |
| P/E Ratio | ★ $14.67 | $22.35 |
| Revenue Growth | 13.83 | ★ 41.60 |
| 52 Week Low | $56.70 | $134.65 |
| 52 Week High | $76.41 | $247.05 |
| Indicator | ES | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 36.34 |
| Support Level | $64.91 | $159.42 |
| Resistance Level | $68.84 | $193.26 |
| Average True Range (ATR) | 1.25 | 6.17 |
| MACD | -0.07 | -0.11 |
| Stochastic Oscillator | 35.12 | 4.19 |
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It plans to sell Aquarion in 2026. The company exited most of its unregulated businesses in 2006.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.